ABT vs ABUS · P/E 25, rev $44.33B vs P/E 5.4, rev $6.2M
Abbott Laboratories (ABT) versus Arbutus Biopharma Corp (ABUS) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Not investment advice. Open the ABT and ABUS stock pages for the full models.
Not investment advice.